Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Juni 2013

Planlagt Fastgjort Låst Flyttet Genmab
505 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    Plextoren
    wrote on sidst redigeret af
    #494

    https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=269125003&sourcecode=djn

    1 Reply Last reply
    0
    • J Offline
      J Offline
      JKY_VH
      wrote on sidst redigeret af
      #495

      Tak Plex, bestemt interessant

      1 Reply Last reply
      0
      • G Offline
        G Offline
        gentogen
        wrote on sidst redigeret af
        #496

        Dr. Janine Schuurman, Director Strategic Research at Genmab, will give a presentation on the efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange at the International Conference on monoclonal antibodies and cancer stem cells that will be held from 24th to the 26th June 2013

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #497

          Link Preview Image
          The FDA's Cancer Czar Says He Can't Approve New Drugs Fast Enough

          Dr. Richard Pazdur Maybe more than any other person alive, Richard Pazdur, the director of the Food and Drug Administration's Office of Oncology and Hematology Products, personifies the tension between the need to get new drugs to patients fast and the competing desire to make sure they are safe and effective [...]

          favicon

          Forbes (www.forbes.com)

          1 Reply Last reply
          0
          • JørgenVarnæsJ Offline
            JørgenVarnæsJ Offline
            JørgenVarnæs
            wrote on sidst redigeret af
            #498

            tak for den artikel solsen - jeg bed mærke i, at Pazdur specifikt nævnte Hazard Ratio som del af grunden til at afvise...

            1 Reply Last reply
            0
            • G Offline
              G Offline
              gentogen
              wrote on sidst redigeret af
              #499

              Ja, men det går vel bare på, at fimaet i sin ansøgning slet ikke havde regnet på nogen ratio

              1 Reply Last reply
              0
              • MadsSkjernM Offline
                MadsSkjernM Offline
                MadsSkjern
                wrote on sidst redigeret af
                #500

                Der bliver kamp til stregen på cd38 antistof markedet: http://www.reuters.com/article/2013/06/26/nj-morphosys-idUSnBw266538a+100+BSW20130626

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #501

                  Har lige skrevet et indlæg om det - ja den er ikke god. Nok den værste partner for Genmab/Janssen

                  1 Reply Last reply
                  0
                  • L Offline
                    L Offline
                    lom
                    wrote on sidst redigeret af
                    #502

                    Jeg tænker nu at det er ok for GEN, da Janssen må speede op. Og som du skriver er "vi" et år foran. Man kan jo heller ikke forvente eller tro at de andre bare sidder med hænderne i skødet

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #503

                      Det bedste ville jo være, hvis MOM202 ikke viste effekt, for så havde Genmab lavet noget virkelig unikt. Men konkurrence er jo ikke altid dårlig, så der kommer også gode ting ud af det.

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gentogen
                        wrote on sidst redigeret af
                        #504

                        Omvendt beviser det vel bare, at Daratumumab ses som den værste konkurrent af konkurrenten

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #505

                          Præcis

                          1 Reply Last reply
                          0
                          • J Offline
                            J Offline
                            JKY_VH
                            wrote on sidst redigeret af
                            #506

                            God ide at Jyske Quant koncentrerer sig om charms i stedet for Genmab. Så kommer deres "ekspertise" til rette http://www.proinvestor.com/investornyt/69776/pandora-jyske-bank-haever-anbefaling-til-kob-opd

                            1 Reply Last reply
                            0

                            Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                            Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                            With your input, this post could be even better 💗

                            Tilmeld Log ind

                            • Log ind

                            • Har du ikke en konto? Tilmeld

                            • Login or register to search.
                            • First post
                              Last post
                            0
                            • Debatforum
                            • Seneste
                            • Populære
                            • Bruger